Isradipine is a new dihydropyridine calcium antagonist with a high degree of selectivity for
the coronary, cerebral, and skeletal muscle vasculature. The drug has minimal depressant …

Male patients with supine diastolic blood pressures above 95 mmHg after placebo therapy
received twice daily isradipine (Dynacirc; Sandoz) 1.25, 2.5 or 5.0 mg for 12 weeks. Blood …

In this multicenter, placebo-controlled study, 16 patients with mild to moderate essential
hypertension were treated with 10 mg/day isradipine retard (PN 200-110, Lomir SRO, CAS …

Myocardial hypertrophy is a response to many diseases, above all hypertension, that
involves morphological and functional damage and may be the basis for the development of …

This multicenter trial compared the efficacy and safety of isradipine and enalapril in 160
patients with essential hypertension. Patients received isradipine or enalapril for 10 weeks …

Isradipine (Sandoz PN 200‐110), a new dihydropyridine calcium channel antagonist, was
evaluated in a randomized, double‐blind, placebo‐controlled trial for antihypertensive …

Based on pooled data from three randomized placebo-controlled dose-finding studies in a
total of 489 patients, the dose-response relationship for efficacy and adverse events was …

These are the preliminary data of an open multicenter trial of antihypertensive treatment with
isradipine as monotherapy (dose, 4.55±0.56 mg twice daily; n= 11) or isradipine (7.5±0.63 …

In a double-blind parallel-group randomized study, 28 patients with essential hypertension
(World Health Organization class I/II) were allocated in equal numbers to one of two groups …

Isradipine is a dihydropyridine calcium-entry blocking agent with pronounced vasodilator
activity and no significant cardiac effects at clinical doses, a desirable profile for an …